Rivastigmine for dementia associated with Parkinson's disease. - Wikidata - thesis-toulmin - TriplyDB

Rivastigmine for dementia associated with Parkinson's disease.

Rivastigmine for dementia associated with Parkinson's disease.

http://www.wikidata.org/entity/Q33983707

about

Executive dysfunction in Parkinson's disease and timing deficits Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s Disease Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease Cholinesterase inhibitors for Parkinson's disease dementia Quetiapine in the treatment of psychosis in Parkinson's disease Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders Functional neuroimaging in Parkinson's disease Mild cognitive impairment in Parkinson's disease.Structural studies ofPseudomonasandChromobacteriumω-aminotransferases provide insights into their differing substrate specificity Rational pharmacological approaches for cognitive dysfunction and depression in Parkinson's disease Parkinson's Disease and Cognitive Impairment Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.Parkinson Disease and Dementia.Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.Treatment of psychosis and dementia in Parkinson's disease.Treatment of advanced Parkinson's disease The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.Benzodiazepine Use and Risk of Developing Alzheimer's Disease: A Case-Control Study Based on Swiss Claims Data.Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.Third degree atrioventricular block associated with treatment with rivastigmine transdermal patch Cholinesterase inhibitors: drugs looking for a disease?Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies.A pilot study of rivastigmine in the treatment of delirium after stroke: a safe alternative.Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease Genetic variation of CHRNA4 does not modulate attention in Parkinson's disease Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.Parkinson's disease: the quintessential neuropsychiatric disorder Dementia and cognitive impairment: epidemiology, diagnosis, and treatment.Parkinson's disease dementia: a diminished role for the Lewy body.Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.Lewy body dementia: the caregiver experience of clinical care.Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.

P2860

Q21090466-D1C415F7-35AB-4AEB-B208-F999E740D610 Q24188194-5CDFAB69-E532-40B7-A415-9B66CD738BDF Q24201307-FE24129C-653C-4E3C-9C95-CE6473A17E2F Q24244668-51081625-B429-4726-AB2D-7DE69C9897F9 Q24628941-B7F8E30E-C17C-486B-B1B5-A48B65468322 Q24678238-95683BCB-144E-41E0-AD8E-F9E409154C1C Q24680260-9238A902-B85B-4733-A4F6-201D7F4AB1C5 Q26745661-2D535ACA-95F0-44D5-B3CF-31B7E698C7D9 Q26765419-DC322F87-77DF-43C7-A739-50A043ED3873 Q27013767-6D0C3477-7F42-4FC4-B059-2340FF713099 Q27021220-2751B6C8-A9A0-4F6E-BCBC-F470BAA4A316 Q27676955-55A0CE16-2FD0-4823-81D5-C76F73477380 Q28084380-958E4B84-3DCE-403A-B9EE-2A2F32E0F181 Q30239814-F2B49344-7585-4F56-A94A-8EB5A3F73746 Q30244035-9BA4E721-AC8E-4A20-93EF-BE26E544E8CB Q30248574-3D9DCD7B-A9B5-44A8-A91A-3CE03999D935 Q30250276-2ED4F808-0923-4E8C-8281-EC8E96AE0AA8 Q30358337-311BDD60-ACC4-4CB7-B7CA-CD7A3A5A5630 Q30476968-3962D9B9-087D-4D2A-8BF9-807CC8F6C76A Q31145409-D0538863-D219-4731-AF65-1EB9A2113F2D Q31154313-C0338F32-E54E-4F6D-A28D-79152AFC9297 Q31155412-5D980846-DF9B-452D-AD11-F7828F647311 Q33160127-9DF1BEA1-1AA5-4C87-8F0E-425213DB14A8 Q33162691-326ED5D5-C54C-464F-A0D0-76391D26F80F Q33238993-14463C84-FAEB-4122-9C6D-6D5E74F5890B Q33260251-BE0A1BAA-DCD0-43B9-AADE-A0709882DC8C Q33267768-CA591B2A-0901-4419-B462-9BB2FE3A2491 Q33370687-C7868C8C-892F-4B14-8190-F566F941BE7C Q33596451-6F067AB7-BA94-445B-AAD8-9071C92AA709 Q33607256-D060683B-2434-4723-8863-836A8D3F0CDC Q33685603-F2FEFE64-164F-4532-B0B0-74E9988C59FE Q33708946-86CC02FA-48A8-45B3-90AC-F159B0B7B846 Q33724257-475A125C-4311-40A0-9F3D-493BB99491F6 Q33917094-B3B28ECE-3336-4CAA-AFFC-B612164D63A1 Q33924014-276BA81D-B156-4678-9BFD-6EC0D958B016 Q34024575-8C85855F-988D-4C41-AF77-C449168A60A6 Q34032505-93D69CF7-93D4-4DA9-A1B9-E953845E4848 Q34044014-96E9771D-5D6A-4D18-9CA5-B68FE206E218 Q34051079-2A38BFD6-07D3-49F8-815E-7DEBC1A375DF Q34128361-57D0AC81-9694-4D1B-8AD5-288704B94E5C

P2860

Rivastigmine for dementia associated with Parkinson's disease.

http://www.wikidata.org/entity/Q33983707

description

2004 nî lūn-bûn

@nan

2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Rivastigmine for dementia associated with Parkinson's disease.

@ast

Rivastigmine for dementia associated with Parkinson's disease.

@en

type

label

Rivastigmine for dementia associated with Parkinson's disease.

@ast

Rivastigmine for dementia associated with Parkinson's disease.

@en

prefLabel

Rivastigmine for dementia associated with Parkinson's disease.

@ast

Rivastigmine for dementia associated with Parkinson's disease.

@en

P1433

Q33983707-D8A18561-5BB1-491F-8826-65FE60933D74

P1476

Q33983707-989110C3-1F27-4340-93BB-265298DB8374

P2093

Q33983707-05CA612F-C27B-4F45-9B91-0F2EA7FE718C

Q33983707-167084B6-77A4-45E1-9A25-108DE0417652

Q33983707-1CA58466-4D61-426B-9A0B-F3D35E30F423

Q33983707-370D498C-D873-4E60-ABDD-E1CF522BF07F

Q33983707-6BD1F1F0-7075-4D5F-AD9C-FE89FE984FAA

Q33983707-8DAAB37F-F7D1-4662-AB18-69D4151A2C4E

Q33983707-957165D0-3DC4-4BC5-82D4-1550E8F2392A

Q33983707-A441155B-7285-4965-AE68-3330601C208F

Q33983707-AC8AE5A7-0C03-4D03-9DFF-664D13811BE9

Q33983707-F1C20C9C-B90F-4B58-B2F0-05FEB59D0B67

P304

Q33983707-474C6F12-EDA3-420E-8171-E0222DED2D43

P31

Q33983707-A9E1D98B-C359-4372-8E60-CD53CADA2487

P356

Q33983707-C243D926-D964-4CB1-8AC8-AAC38DCAED57

P407

Q33983707-61D5A136-E1BB-4AE2-97E8-6ADFE706FF0A

P433

Q33983707-DDF6AD5A-C982-4628-BF8F-9A61EAE717FE

P478

Q33983707-7C2BB468-E7D6-4932-B3B0-63C8CB97F080

P50

Q33983707-4A6BEDE7-C9E1-4264-8EA9-25FA8414DAA9

Q33983707-853477C1-C651-47B3-8322-A028606D249B

Q33983707-B4FAED96-76B7-4E3B-B2D5-16CE4752C508

Q33983707-CEF4C76A-1DBF-406C-9ABF-8E6225CA8224

Q33983707-D56E020E-B9F2-4908-9088-2A44EF9B6D03

P577

Q33983707-993E7293-EFAF-44B7-BE32-666D7C8EF49A

P698

Q33983707-8DA2E8AA-52CB-49EF-8DE8-6B150A68DFEE

P921

Q33983707-3687CA81-8DB1-4903-9218-91F3C57EDB9F

Q33983707-E9E9710B-0781-4116-8B1E-954A72685F98

P356

P1433

The New England Journal of Medicine

P1476

Rivastigmine for dementia associated with Parkinson's disease.

@en

P2093

Alain Robillard

http://www.w3.org/2001/XMLSchema#string

Alberto Albanese

http://www.w3.org/2001/XMLSchema#string

E Jane Byrne

http://www.w3.org/2001/XMLSchema#string

Erik Wolters

http://www.w3.org/2001/XMLSchema#string

Franck Durif

http://www.w3.org/2001/XMLSchema#string

Mario M Rosa

http://www.w3.org/2001/XMLSchema#string

Murat Emre

http://www.w3.org/2001/XMLSchema#string

Peter P De Deyn

http://www.w3.org/2001/XMLSchema#string

Peter Quarg

http://www.w3.org/2001/XMLSchema#string

Roger Lane

http://www.w3.org/2001/XMLSchema#string

P304

2509-2518

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA041470

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

351

http://www.w3.org/2001/XMLSchema#string

P50

Günther Deuschl

Andrew John Lees

Jaime Kulisevsky

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15590953

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease